Report covers a patient with paralysis walking in Manhattan using a Wandercraft exoskeleton

On November 10, 2026, the-gadgeteer.com reported on a case in Manhattan involving a patient with paralysis walking with a Wandercraft exoskeleton.

The report covers a situation in which a Wandercraft exoskeleton is involved in a patient’s walking, offering a basis for considering operating conditions that differ from those for deploying robots in industrial settings. However, the article alone does not establish treatment effectiveness or how widely the technology is used.

An important point in reading this report is to consider Wandercraft’s product offerings separately by use rather than grouping them together as a single “humanoid robot” business. We reported on the commercial rollout of an industrial machine in Wandercraft announces commercial rollout of industrial humanoid “Calvin-40”. The current article, by contrast, covers a clinical and rehabilitation setting involving walking by a patient with paralysis. While both involve robotics, the outcomes to evaluate and operating conditions are likely to differ between deploying robots for factory work and supporting patients’ walking. We have reported on Wandercraft’s home-use exoskeleton in Wandercraft begins U.S. commercial rollout of self-balancing exoskeleton Eve. Taken together with the current report, articles about the company cover different settings: industrial humanoids, home-use exoskeletons, and clinical and rehabilitation use. However, the information provided does not establish whether these are linked by shared hardware, control technology or sales operations. Technical commonalities between products should not be inferred solely from their names or shared company ownership. Wandercraft’s plan to deploy humanoid robots for Renault reported covered a planned deployment for industrial use. Comparing it with the current clinical and rehabilitation case requires distinguishing not only the number of units deployed and the progress of plans, but also the actual operating environments and the outcomes being measured. The case described in the article does not allow conclusions to be generalized about effects on patients, the extent of adoption in medical settings or the scope of insurance coverage. The next points to check are how the number of users, continued use and level of support are evaluated, as well as how facility operations and involvement by professionals are incorporated. The current report does not provide enough information to assess these points. See the original source for details.